Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies (ADPT) to Buy from Neutral with a $9 price target Since October 2024, ...

We recently compiled a list of the 10 Hot Growth Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against ...

Goldman Sachs analyst Salveen Richter initiated coverage of the company’s stock with a “Buy” rating and a price objective of $42. As per the analyst, Summit Therapeutics Inc. (NASDAQ ...

Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Yigal Nochomovitz; Analyst; Citigroup Inc. Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Yigal Nochomovitz; Analyst; Citigroup Inc. Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals ...

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, following the Q4 report. The firm awaits the Phase 3 ...

NEW ULM–Kenneth A. Richter, age 82, of New Ulm passed away Monday, February 24, 2025 at his home in New Ulm. Mass of Christian Burial will be 11:00 a.m. Monday, March, 3rd, 2025 at the Cathedral ...

Mr. Richter is a journalist at work on a book about the history of corporate Germany. He wrote from Berlin. It’s been a grim election season in Germany. Spanning the harsh winter months ...